Molecular Templates’ Chapter 11 case closed on August 11, 2026, after its debt-for-equity plan became effective and a liquidating trust took over the wind-down. The trustee reported preparing a final distribution to eligible unsecured creditors; a final claims register Dkt. 281 was filed on September 1, 2026.

Molecular Templates, Inc.’s Chapter 11 case closed on August 11, 2026, under the final decree Dkt. 275. Its plan was confirmed on July 7, 2025, and became effective on July 18, 2025, transferring specified assets to a liquidating trust and vesting the remaining assets in the reorganized debtors, according to the effective-date notice Dkt. 194.

The clinical-stage biopharmaceutical company filed for Chapter 11 on April 20, 2025, after unsuccessful efforts to raise capital or sell assets, the termination of its Bristol Myers Squibb collaboration, and a liquidity shortfall. It had ceased operations and terminated its employees at the end of 2024. The first-day declaration Dkt. 15 describes the lender-supported restructuring and wind-down.

The confirmation order Dkt. 186 provided for a debt-for-equity exchange with secured lender K2 HealthVentures and established the trust to administer retained assets and distributions. Existing equity was canceled, while general unsecured creditors were to share in specified distribution and avoidance-action proceeds; the plan projected a 1% to 5% recovery for that class. During the case, the final financing order Dkt. 113 authorized up to $3 million in new-money financing, including a discretionary $1 million tranche, and a $9 million roll-up of prepetition obligations.

In the final-decree motion Dkt. 267, the trustee reported that claims had been substantially reconciled, assets of value liquidated, and distributions made, with a final distribution to eligible unsecured creditors being prepared subject to required tax forms. The final decree Dkt. 275 preserved the trustee’s ability to dispute claims in an appropriate forum, and the final claims register Dkt. 281 was filed on September 1, 2026.

Molecular Templates’ Chapter 11 case closed on August 11, 2026, after its debt-for-equity plan became effective and a liquidating trust took over the wind-down. The trustee reported preparing a final distribution to eligible unsecured creditors; a final claims register Dkt. 281 was filed on September 1, 2026.

Molecular Templates, Inc.’s Chapter 11 case closed on August 11, 2026, under the final decree Dkt. 275. Its plan was confirmed on July 7, 2025, and became effective on July 18, 2025, transferring specified assets to a liquidating trust and vesting the remaining assets in the reorganized debtors, according to the effective-date notice Dkt. 194.

The clinical-stage biopharmaceutical company filed for Chapter 11 on April 20, 2025, after unsuccessful efforts to raise capital or sell assets, the termination of its Bristol Myers Squibb collaboration, and a liquidity shortfall. It had ceased operations and terminated its employees at the end of 2024. The first-day declaration Dkt. 15 describes the lender-supported restructuring and wind-down.

The confirmation order Dkt. 186 provided for a debt-for-equity exchange with secured lender K2 HealthVentures and established the trust to administer retained assets and distributions. Existing equity was canceled, while general unsecured creditors were to share in specified distribution and avoidance-action proceeds; the plan projected a 1% to 5% recovery for that class. During the case, the final financing order Dkt. 113 authorized up to $3 million in new-money financing, including a discretionary $1 million tranche, and a $9 million roll-up of prepetition obligations.

In the final-decree motion Dkt. 267, the trustee reported that claims had been substantially reconciled, assets of value liquidated, and distributions made, with a final distribution to eligible unsecured creditors being prepared subject to required tax forms. The final decree Dkt. 275 preserved the trustee’s ability to dispute claims in an appropriate forum, and the final claims register Dkt. 281 was filed on September 1, 2026.